此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

联合化疗联合或不联合自体干细胞移植治疗中枢神经系统 B 细胞淋巴瘤患者

2026年8月31日 更新者：Alliance for Clinical Trials in Oncology

清髓性与非清髓性巩固化疗治疗新诊断原发性中枢神经系统 B 细胞淋巴瘤的随机 II 期试验

The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.

研究概览

地位

完全的

条件

干预/治疗

详细说明

Primary Objective:

To compare the two-year progression-free survival (PFS) of patients treated with the myeloablative consolidation treatment strategy of HDT/ASCT versus those treated with non-myeloablative consolidation chemotherapy with cytarabine and etoposide

Secondary Objectives:

  1. To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine
  2. To compare the overall survival (OS) of patients treated with the consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine
  3. To assess the toxicities associated with consolidation HDT/ASCT versus consolidation consisting of etoposide and cytarabine
  4. To determine diffusion MRI metrics (ADCmini, ADC25%, and ADCmean) prior to induction chemotherapy, after one full induction chemotherapy cycle, and at the end of induction chemotherapy as a predictor of response and outcome (CALGB 581101)
  5. To determine brain FDG-PET metrics (tumor SUV and tumor versus background SUV) prior to induction chemotherapy, after one full induction chemotherapy cycle, and at the end of induction chemotherapy as a predictor of response and outcome (CALGB 581101)
  6. To determine whether low baseline ADC measurements are associated with shorter PFS and OS (CALGB 581101)
  7. To determine whether reduction in tumor SUV by > 25% on brain FDG-PET/CT after one cycle of induction therapy is associated with improved PFS and OS (CALGB 581101)
  8. To determine which IHC-based biomarkers are predictive of an adverse prognosis (CALGB 151113)
  9. To determine which IHC-based biomarkers are predictive of a favorable prognosis (CALGB 151113) for BCL6 (B-cell CLL/lymphoma 6), and STAT 6 (signal transducer and activator of transcription 6, interleukin-4 induced)
  10. To analyze tumor tissue for gene expression profiles, and to correlate these profiles with treatment outcomes (CALGB 151113)
  11. To determine whether CSF proteome is a predictor of outcomes (prognostic marker) irrespective of treatment arm (CALGB 151113) for (IL-10 (interleukin 10) and C3 (complement component 3)
  12. To assess the neurocognitive function of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy (etoposide and cytarabine) as measured by serial administration of the International PCNSL Collaborative Group (IPCG) neurocognitive battery and evaluate the long-term survivorship differences between the two arms (CALGB 71105)

研究类型

介入性

注册 (实际的)

113

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • Alaska
      • Anchorage、Alaska、美国、98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage、Alaska、美国、99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage、Alaska、美国、99508
        • Alaska Oncology and Hematology LLC
      • Anchorage、Alaska、美国、99508
        • Alaska Women's Cancer Care
      • Anchorage、Alaska、美国、99508
        • Anchorage Oncology Centre
      • Anchorage、Alaska、美国、99508
        • Katmai Oncology Group
      • Anchorage、Alaska、美国、99508
        • Providence Alaska Medical Center
      • Anchorage、Alaska、美国、99504
        • Anchorage Radiation Therapy Center
    • California
      • Burbank、California、美国、91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • La Jolla、California、美国、92093
        • UC San Diego Moores Cancer Center
      • Sacramento、California、美国、95817
        • University of California Davis Comprehensive Cancer Center
      • San Francisco、California、美国、94115
        • UCSF Medical Center-Mount Zion
      • San Francisco、California、美国、94143
        • UCSF Medical Center-Parnassus
    • Connecticut
      • New Haven、Connecticut、美国、06520
        • Yale University
    • Florida
      • Tampa、Florida、美国、33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University/Winship Cancer Institute
    • Idaho
      • Boise、Idaho、美国、83712
        • Saint Luke's Mountain States Tumor Institute
      • Fruitland、Idaho、美国、83619
        • Saint Luke's Mountain States Tumor Institute - Fruitland
      • Meridian、Idaho、美国、83642
        • Saint Luke's Mountain States Tumor Institute - Meridian
      • Nampa、Idaho、美国、83686
        • Saint Luke's Mountain States Tumor Institute - Nampa
      • Twin Falls、Idaho、美国、83301
        • Saint Luke's Mountain States Tumor Institute-Twin Falls
    • Illinois
      • Chicago、Illinois、美国、60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago、Illinois、美国、60612
        • University of Illinois
    • Indiana
      • Richmond、Indiana、美国、47374
        • Reid Health
    • Kansas
      • Kansas City、Kansas、美国、66160
        • University of Kansas Cancer Center
    • Kentucky
      • Crestview Hills、Kentucky、美国、41017
        • Oncology Hematology Care Inc-Crestview
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • Tulane University Health Sciences Center
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02115
        • Brigham and Women's Hospital
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Battle Creek、Michigan、美国、49017
        • Bronson Battle Creek
      • Grand Rapids、Michigan、美国、49503
        • Spectrum Health at Butterworth Campus
      • Grand Rapids、Michigan、美国、49503
        • Mercy Health Saint Mary's
      • Kalamazoo、Michigan、美国、49007
        • West Michigan Cancer Center
      • Kalamazoo、Michigan、美国、49007
        • Bronson Methodist Hospital
      • Kalamazoo、Michigan、美国、49001
        • Borgess Medical Center
      • Muskegon、Michigan、美国、49444
        • Mercy Health Mercy Campus
      • Niles、Michigan、美国、49120
        • Lakeland Community Hospital
      • Reed City、Michigan、美国、49677
        • Spectrum Health Reed City Hospital
      • Saint Joseph、Michigan、美国、49085
        • Marie Yeager Cancer Center
      • Saint Joseph、Michigan、美国、49085
        • Lakeland Hospital
      • Traverse City、Michigan、美国、49684
        • Munson Medical Center
      • Wyoming、Michigan、美国、49519
        • Metro Health Hospital
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
    • Nebraska
      • Omaha、Nebraska、美国、68198
        • University of Nebraska Medical Center
    • New York
      • New York、New York、美国、10065
        • Weill Medical College of Cornell University
      • Rochester、New York、美国、14642
        • University of Rochester
      • Stony Brook、New York、美国、11794
        • Stony Brook University Medical Center
      • Syracuse、New York、美国、13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke University Medical Center
    • Ohio
      • Centerville、Ohio、美国、45459
        • Dayton Physicians LLC-Miami Valley South
      • Cincinnati、Ohio、美国、45242
        • Oncology Hematology Care Inc-Blue Ash
      • Cincinnati、Ohio、美国、45202
        • Oncology Hematology Care Inc-Eden Park
      • Cincinnati、Ohio、美国、45211
        • Oncology Hematology Care Inc-Mercy West
      • Cincinnati、Ohio、美国、45236
        • Oncology Hematology Care Inc-Kenwood
      • Cincinnati、Ohio、美国、45230
        • Oncology Hematology Care Inc - Anderson
      • Dayton、Ohio、美国、45406
        • Good Samaritan Hospital - Dayton
      • Dayton、Ohio、美国、45409
        • Miami Valley Hospital
      • Dayton、Ohio、美国、45415
        • Dayton Physicians LLC-Samaritan North
      • Dayton、Ohio、美国、45415
        • Samaritan North Health Center
      • Dayton、Ohio、美国、45420
        • Dayton NCI Community Oncology Research Program
      • Fairfield、Ohio、美国、45014
        • Oncology Hematology Care Inc-Healthplex
      • Findlay、Ohio、美国、45840
        • Blanchard Valley Hospital
      • Findlay、Ohio、美国、45840
        • Armes Family Cancer Center
      • Findlay、Ohio、美国、45840
        • Orion Cancer Care
      • Franklin、Ohio、美国、45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Franklin、Ohio、美国、45005
        • Dayton Physicians LLC-Atrium
      • Greenville、Ohio、美国、45331
        • Wayne Hospital
      • Greenville、Ohio、美国、45331
        • Dayton Physicians LLC-Wayne
      • Kettering、Ohio、美国、45429
        • Kettering Medical Center
      • Kettering、Ohio、美国、45409
        • Greater Dayton Cancer Center
      • Middletown、Ohio、美国、45042
        • Dayton Physicians LLC-Signal Point
      • Sidney、Ohio、美国、45365
        • Dayton Physicians LLC-Wilson
      • Springfield、Ohio、美国、45505
        • Springfield Regional Medical Center
      • Springfield、Ohio、美国、45504
        • Springfield Regional Cancer Center
      • Troy、Ohio、美国、45373
        • Upper Valley Medical Center
      • Troy、Ohio、美国、45373
        • Dayton Physicians LLC-Upper Valley
    • Oklahoma
      • Tulsa、Oklahoma、美国、74136
        • Surgical Associates Inc
      • Tulsa、Oklahoma、美国、74146
        • Warren Clinic Oncology-Tulsa
    • Oregon
      • Bend、Oregon、美国、97701
        • Saint Charles Health System
      • Clackamas、Oregon、美国、97015
        • Clackamas Radiation Oncology Center
      • Clackamas、Oregon、美国、97015
        • Providence Oncology and Hematology Care Southeast
      • Coos Bay、Oregon、美国、97420
        • Bay Area Hospital
      • Milwaukie、Oregon、美国、97222
        • Providence Milwaukie Hospital
      • Newberg、Oregon、美国、97132
        • Providence Newberg Medical Center
      • Oregon City、Oregon、美国、97045
        • Providence Willamette Falls Medical Center
      • Portland、Oregon、美国、97213
        • Providence Portland Medical Center
      • Portland、Oregon、美国、97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Danville、Pennsylvania、美国、17822
        • Geisinger Medical Center
      • Lewistown、Pennsylvania、美国、17044
        • Lewistown Hospital
      • Pittsburgh、Pennsylvania、美国、15232
        • University of Pittsburgh Cancer Institute (UPCI)
    • Utah
      • Salt Lake City、Utah、美国、84112
        • Huntsman Cancer Institute/University of Utah
    • Vermont
      • Berlin Corners、Vermont、美国、05602
        • Central Vermont Medical Center/National Life Cancer Treatment
      • Burlington、Vermont、美国、05401
        • University of Vermont Medical Center
      • Burlington、Vermont、美国、05405
        • University of Vermont College of Medicine
    • Virginia
      • Richmond、Virginia、美国、23298
        • Virginia Commonwealth University/Massey Cancer Center
    • Washington
      • Aberdeen、Washington、美国、98520
        • Providence Regional Cancer System-Aberdeen
      • Anacortes、Washington、美国、98221
        • Cancer Care Center at Island Hospital
      • Bellevue、Washington、美国、98005
        • Swedish Cancer Institute-Eastside Oncology Hematology
      • Bellingham、Washington、美国、98225
        • PeaceHealth Saint Joseph Medical Center
      • Centralia、Washington、美国、98531
        • Providence Regional Cancer System-Centralia
      • Edmonds、Washington、美国、98026
        • Swedish Medical Center-Edmonds
      • Everett、Washington、美国、98201
        • Providence Regional Cancer Partnership
      • Issaquah、Washington、美国、98029
        • Swedish Cancer Institute-Issaquah
      • Lacey、Washington、美国、98503
        • Providence Regional Cancer System-Lacey
      • Longview、Washington、美国、98632
        • PeaceHealth Saint John Medical Center
      • Seattle、Washington、美国、98109
        • Fred Hutchinson Cancer Research Center
      • Seattle、Washington、美国、98109
        • Seattle Cancer Care Alliance
      • Seattle、Washington、美国、98195
        • University of Washington Medical Center
      • Seattle、Washington、美国、98107
        • Swedish Medical Center-Ballard Campus
      • Seattle、Washington、美国、98104
        • Minor and James Medical PLLC
      • Seattle、Washington、美国、98104
        • Pacific Gynecology Specialists
      • Seattle、Washington、美国、98112
        • Group Health Cooperative-Seattle
      • Seattle、Washington、美国、98122-4307
        • Swedish Medical Center-First Hill
      • Shelton、Washington、美国、98584
        • Providence Regional Cancer System-Shelton
      • Spokane、Washington、美国、99204
        • Rockwood Cancer Treatment Center-DHEC-Downtown
      • Spokane Valley、Washington、美国、99216
        • Rockwood Clinic Cancer Treatment Center-Valley
      • Vancouver、Washington、美国、98664
        • PeaceHealth Southwest Medical Center
      • Vancouver、Washington、美国、98684
        • Compass Oncology Vancouver
      • Walla Walla、Washington、美国、99362
        • Providence Saint Mary Regional Cancer Center
      • Yakima、Washington、美国、98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
      • Yelm、Washington、美国、98597
        • Providence Regional Cancer System-Yelm
    • Wisconsin
      • La Crosse、Wisconsin、美国、54601
        • Mayo Clinic Health System-Franciscan Healthcare
      • Madison、Wisconsin、美国、53792
        • University of Wisconsin Hospital and Clinics

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

  1. Documentation of Disease: Diagnosis of primary CNS diffuse large B-cell lymphoma confirmed by one of the following: brain biopsy or resection, cerebrospinal fluid and vitreous fluid.
  2. Other Lymphomas: Patients must have no evidence or history of non-Hodgkin lymphoma (NHL) outside of CNS.
  3. Previous Treatment: Patients must have no prior chemotherapy or radiation therapy for lymphoma.
  4. Age- Patients must be between the ages of 18 and 75 years.
  5. Karnofsky Performance Scale - Patients must measure Karnofsky Performance Scale ≥ 30 (≥ 50 for patients ages 60-70).
  6. Pregnancy and Nursing Status - Patients must be non-pregnant and non-nursing; women of childbearing potential must have a negative serum or urine pregnancy test 10-14 days prior to registration; in addition, women and men of childbearing potential must commit to use an effective form of contraception throughout their participation in this study; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom)
  7. HIV - Patients must have negative HIV serology.
  8. Hepatitis - Patients must have negative HCV serology (unless HBsAb positive patient has recently received HBV vaccine, in this case HBcAb should be negative). All patients must be screened for hepatitis B infection before starting treatment. Those patients who test positive for hepatitis B should be closely monitored for evidence of active HBV infection and hepatitis during and for several months after rituximab treatment. PCNSL patients with a history of hepatitis B infection should be treated with entecavir or lamivudine (physician discretion for choice of drug) as antiviral prophylaxis to prevent hepatitis B reactivation.
  9. Organ Transplant or Immunosuppressant Therapy - Patient must have no history of organ transplantation or ongoing immunosuppressant therapy.
  10. Required Initial Laboratory Values: ANC ≥ 1500/mcL, AST and ALT < 2 x upper limit of normal (ULN), total bilirubin ≤ 3 mg/dL, creatinine clearance ≥ 50 mL/min, platelet count ≥ 100,000/mcL

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
其他：Arm I

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
药品：脑脊液
程序：干细胞移植
药品：carmustine

Given IV

药品：thiotepa

Given IV
其他：Arm II

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
药品：脑脊液
药品：cytarabine

Given IV

药品：etoposide

Given IV

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Progression Free Survival
大体时间：2 years

The primary endpoint is to compare the two-year progression-free survival (PFS) of patients treated with the myeloablative consolidation treatment strategy of HDT/ASCT versus those treated with non-myeloablative consolidation chemotherapy with cytarabine and etoposide.

PFS time = time from Registration to earliest date of Progression or Death due to any cause, censoring non-progressed and alive patients at the date of last disease status evaluation.

Response will be defined using the modified IPCG criteria. Progressive disease is defined as > 25% increase in contrast-enhancing CNS (brain and spine if latter abnormal at baseline) disease, appearance of any new, measurable (>/= 10mm) contrast-enhancing disease or recurrent or new ocular or CSF disease.
2 years

次要结果测量

结果测量
措施说明
大体时间
Event Free Survival
大体时间：2 years

To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine.

EFS event = same definition as PFS with non-protocol treatment also considered an event
2 years
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
大体时间：7 years

Number of patients reporting at least one adverse event at least possibly related to treatment.
7 years
Overall Survival
大体时间：2 years

To compare the overall survival (OS) of patients treated with the consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine.

OS event = Registration/Randomization to Death due to any cause
2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Alliance for Clinical Trials in Oncology

合作者

National Cancer Institute (NCI)

调查人员

  • 学习椅：Tracy Batchelor, MD, MPH、Massachusetts General Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年9月1日

初级完成 (实际的)

2021年1月14日

研究完成 (实际的)

2022年2月24日

研究注册日期

首次提交

2012年1月13日

首先提交符合 QC 标准的

2012年1月13日

首次发布 (估计的)

2012年1月18日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年8月31日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CALGB-51101
  • CDR0000721927 (注册表标识符：NCI Physician Data Query)
  • NCI-2012-00110 (注册表标识符：NCI Clinical Trial Reporting Program)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅